#cancer testing #Cayman Islands #George Town #Biomarkers #Cizzle Bio

Cizzle Bio's Groundbreaking Launch in the Cayman Islands

Cizzle Bio, Inc., a pioneering biotechnology firm known for its advanced blood tests for early cancer detection, has recently expanded its global reach by collaborating with Doctors Hospital in the Cayman Islands. This partnership allows the hospital to implement Cizzle Bio’s proprietary CIZ1B lung cancer test, along with the DEX-G2 gastric cancer test, directly in its clinical laboratory. This expansion brings vital cancer screening tools to the Caribbean, enabling patients quicker and more accurate diagnoses of two of the world’s deadliest cancers: lung and gastric cancers.

The introduction of these tests is part of Cizzle Bio’s long-term strategy to increase the accessibility of early cancer detection methods globally, with a special focus on expanding its footprint in the U.S. and international markets. The company holds exclusive licensing rights for its innovative CIZ1B biomarker test across regions including the United States, Canada, and the Caribbean, as well as a worldwide license for the DEX-G2 test. Both tests are currently being advanced towards clinical rollout in the United States, with CIZ1B anticipated to launch soon, followed by DEX-G2 later this year.

Bill Behnke, the founder and CEO of Cizzle Bio, expressed enthusiasm about this new venture: “We are thrilled to partner with Doctors Hospital to bring our biomarker blood tests to Caribbean patients. This agreement reinforces our commitment to enhancing cancer detection through innovative, cost-effective, and reliable methods, detecting cancer at earlier stages when it is most treatable.”

The CIZ1B biomarker test, developed over 30 years of research at the University of York, detects a specific variant of the CIZ1 protein that is closely linked to early lung cancer diagnosis. Similarly, the DEX-G2 test comes from extensive research conducted at the City of Hope Comprehensive Cancer Center and focuses on identifying a novel biomarker signature that shows a high level of specificity for gastric cancer. Both tests integrate seamlessly into standard preventive care and diagnostic workflows, heralding a new era in cancer detection.

David E. Pellow, the director of Ancillary and Support Services at Doctors Hospital, shared his perspective: “At Doctors Hospital, we are dedicated to providing our patients with the most advanced and effective tools for early diagnosis and better health outcomes. Integrating Cizzle Bio’s CIZ1B and DEX-G2 tests into our services enhances our capability to detect cancer earlier, thus promoting proactive and personalized care in our community.”

The addition of these tests is poised to significantly improve the hospital’s cancer screening programs, allowing for minimally invasive and highly accurate detection techniques that inform clinical decisions and enhance patient outcomes.

About Cizzle Bio, Inc.

Cizzle Bio is a biotech company based in Texas, committed to revolutionizing cancer diagnosis through the development of biomarker-based blood tests aimed at early detection of lung and gastric cancers. With a mission to empower patients and healthcare providers, Cizzle Bio seeks innovation and compassion in developing solutions that lead to better health outcomes.

About Doctors Hospital

Established in 2000 as the Chrissie Tomlinson Memorial Hospital (CTMH), Doctors Hospital stands as the premier provider of international-standard healthcare services in the Caribbean, delivering First World health solutions in collaboration with dedicated healthcare providers.

In conclusion, Cizzle Bio's innovative approaches in the Cayman Islands mark a significant step forward in the fight against cancer, offering hope and enhanced diagnostic capabilities to patients and healthcare systems alike.